KKR & Co. Inc. (KKR) has a message for investors chasing the S&P 500: you're probably overpaying, and there are better places to put your money in 2026.

The investment giant's latest "High Grading" outlook argues that while U.S. large-cap valuations look stretched, meaningful opportunities exist for investors willing to venture beyond the usual suspects. Specifically, KKR is pointing toward Asian corporate reforms, a resurgent biotech sector, and critical infrastructure as the next phase of high-quality growth trades.

The Asian Reform Opportunity

KKR's top conviction for 2026 centers on a structural shift happening across Asia—not driven by explosive GDP growth, but by something potentially more valuable: corporate governance overhauls.

The firm highlights Japan and South Korea as particularly compelling opportunities. Companies in these markets are transitioning from "capital heavy to capital light" business models designed to unlock shareholder value. Think of it as corporate spring cleaning with actual financial consequences.

Here's the surprising part: despite posting 50% gains in 2025, roughly 70% of the Korean market still trades below book value. In Japan, that figure is 40%. Compare that to less than 7% in the U.S., and you start to see why KKR views these markets as mispriced relative to their reform potential.

The performance numbers from 2025 tell an interesting story about where investors have already started looking:

Biotech's AI-Powered Comeback

After years of being left behind, biotechnology is emerging as one of the most attractive entry points in public markets, according to KKR.

The firm frames biotech as a "secular growth story" powered by two major tailwinds: aging demographics and the integration of artificial intelligence into drug development. It's not just about developing new treatments anymore—it's about doing it faster and smarter with AI.

Large pharmaceutical companies facing patent cliffs are increasingly hunting for AI-driven pipelines, which creates natural acquisition demand for innovative biotech firms. KKR suggests the sector offers innovation-led growth comparable to the broader tech sector, but at far more reasonable valuations.

For investors looking at biotech exposure, here are some ETF options that have already shown strong momentum:

Infrastructure: The Unglamorous Winner

While KKR remains cautious on speculative data center projects, the firm is decidedly bullish on the unglamorous but essential infrastructure needed to keep the digital economy running—specifically HVAC and cooling systems.

Here's why that matters: AI training clusters require exponentially more cooling capacity than traditional office buildings. All those GPUs churning through machine learning models generate serious heat, which means sustained demand for electrical infrastructure and cooling capacity. It's the classic "picks and shovels" play for the AI boom.

Beyond cooling, KKR points to U.S. Liquefied Natural Gas as a multi-year structural winner. Energy security concerns in Europe and Asia are driving sustained demand, creating what the firm views as a durable investment theme.

Infrastructure ETFs have already delivered solid returns, reflecting growing investor recognition of these trends:

The broader message from KKR is simple: high-quality investment opportunities don't disappear just because the S&P 500 looks expensive. They just move to different places. For 2026, that means looking at Asian reform stories, biotech innovation trading at reasonable prices, and the essential infrastructure powering our increasingly digital world.